studies

non squamous cell - mNSCLC - L1, atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpower-150 (ABCP vs BPC WT), 2018 0.78 [0.64; 0.96] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.76 [0.63; 0.92] 0.77[0.67; 0.89]IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,496moderatenot evaluable progression or deaths (PFS)detailed resultsIMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 0.51 [0.38; 0.68] IMpower-150 (ABCP vs BPC WT), 2018 0.62 [0.52; 0.74] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.61 [0.52; 0.72] 0.60[0.54; 0.67]IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%1,776moderatenot evaluable objective responses (ORR)detailed resultsIMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 1.96 [1.20; 3.19] IMpower-150 (ABCP vs BPC WT), 2018 1.88 [1.38; 2.55] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.95 [1.47; 2.58] 1.92[1.59; 2.33]IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%1,764moderatenot evaluable AE (any grade)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.49 [0.15; 1.65] 0.49[0.15; 1.65]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable AE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.14 [0.86; 1.52] 1.14[0.86; 1.52]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable AE leading to death (grade 5)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.10 [0.60; 2.03] 1.10[0.60; 2.03]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.46 [1.07; 1.99] 1.46[1.07; 1.99]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable SAE (any grade)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.40 [1.05; 1.87] 1.40[1.05; 1.87]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable STRAE (any grade)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.43 [1.02; 2.00] 1.43[1.02; 2.00]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable TRAE (any grade)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.81 [0.43; 1.53] 0.81[0.43; 1.53]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.38 [1.04; 1.83] 1.38[1.04; 1.83]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable TRAE leading to death (grade 5)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01] 1.23[0.50; 3.01]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.06; 16.09] 1.00[0.06; 16.09]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65] 1.00[0.02; 50.65]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.05 [0.58; 1.89] 1.05[0.58; 1.89]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.75 [0.17; 3.37] 0.75[0.17; 3.37]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.45 [0.15; 1.30] 0.45[0.15; 1.30]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.53 [0.49; 13.10] 2.53[0.49; 13.10]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65] 1.00[0.02; 50.65]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 4.04[0.45; 36.32]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65] 1.00[0.02; 50.65]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 5.64 [1.24; 25.63] 5.64[1.24; 25.63]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Epistaxis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59] 8.09[0.43; 153.59]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.31 [0.57; 3.03] 1.31[0.57; 3.03]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.48 [0.85; 2.57] 1.48[0.85; 2.57]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59] 8.09[0.43; 153.59]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hypertension TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.57; 1.78] 1.00[0.57; 1.78]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 4.04[0.45; 36.32]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 4.04[0.45; 36.32]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.77 [0.51; 6.09] 1.77[0.51; 6.09]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.18; 22.26] 2.01[0.18; 22.26]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.91 [0.80; 4.57] 1.91[0.80; 4.57]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.27 [0.83; 1.94] 1.27[0.83; 1.94]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.03 [0.18; 89.56] 4.03[0.18; 89.56]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.50 [0.02; 14.97] 0.50[0.02; 14.97]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01] 1.23[0.50; 3.01]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3.04 [0.61; 15.15] 3.04[0.61; 15.15]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Rash TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 10.14 [0.55; 186.27] 10.14[0.55; 186.27]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 4.04[0.45; 36.32]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.94 [0.47; 1.89] 0.94[0.47; 1.89]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.21 [0.37; 3.99] 1.21[0.37; 3.99]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:03 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 307,165,163,176 - treatments: 1070